Leitung:		Prof. Dr. Angela Brand                                                                           PD Dr. Bodo Lange
Institut:		Maastricht University,                                                                     Max-Planck-Institut für Molekulare Genetik
Homepage:		www.unimaas.nl

Brain Tumor Network	Prof. Peter Lichter	Deutsches Krebsforschungszentrum Heidelberg
Cellular Systems Genomics in Health and Disease	PD Dr. Stefan Wiemann	Deutsches Krebsforschungszentrum Heidelberg
Deciphering Oncogene Dependencies	Dr. Roman Thomas	MPI für neurologische Forschung Köln
Epilepsy and Migraine Integrated Network (EMINet)	Prof. Christian Kubisch	Universität Köln
From Disease Genes to Protein Pathways (DiGTOP)	Prof. Wolfgang Wurst	Helmholtz Zentrum München
Functional and Translational Genomics of Acute Leukemias	Prof. Christian Hagemeier	Charité Berlin
Functional Genomics of Parkinson	Prof. Thomas Gasser	Universität Tübingen
Gene Identification and Functional Analyses in Alzheimer´s Disease	PD Dr. Matthias Riemenschneider	Technische Universität München
Genetics of Alcohol Addiction	Prof. Rainer Spanagel	Zentralinstitut für Seelische Erkrankungen
Genetics of Heart Failure	Prof. Hugo Katus	Universität Heidelberg
Genome Research Network in Pancreatic Cancer	Prof. Thomas M. Gress	Universität Marburg
Genomics of Atherosclerosis	Prof. Heribert Schunkert	Universität Lübeck
German Mental Retardation Network (MRNET)	Prof. André Reis	Universität Erlangen
German Mouse Clinic - Deciphering	Prof. Martin Hrabé de Angelis	Helmholtz Zentrum München
Integrated Genome Network of Prostate Cancer	PD Dr. Holger Sültmann	Deutsches Krebsforschungszentrum Heidelberg
Integrated Genomic Investigation of Colorectal Carcinoma	Prof. Kari Hemminki	Deutsches Krebsforschungszentrum Heidelberg
MHC Haplotype Sequencing: An Intergrated Approach to Common Disease	Dr. Margret Hoehe	MPI für molekulare Genetik Berlin

List of Innovation Alliances in NGFN-Transfer

Integrated Genome Research Network	Coordination	Institution
Anti-malarial Agents	Dr. Birte Sönnichsen	Cenix Bioscience Dresden
Breast Cancer Kit	Prof. Jan G. Hengstler	Leibniz Institut für Arbeitsphysiologie an der Universität Dortmund
Heart Failure Therapy	Prof. Markus Hecker	Universität Heidelberg
Metabolomic signatures of heart failure	Prof. Hugo Katus	Universität Heidelberg
New Tools for the Prevention of Cardiovascular Diseases and Disorders in Chronic Kidney Disease	PD Dr. Joachim Jankowski	Charité Berlin
Protein analysis of formalin-fixed tumor (FFPE) samples	PD Dr. Karl-Friedrich Becker	Technische Universität München
Subgenome Fractionation for High Throughput Sequencing	Dr. Bernhard Korn	Deutsches Krebsforschungszentrum Heidelberg
Whole genome and transcriptome amplification in large biobanks	Prof. H.-Erich Wichmann; Dr. Christian Korfhage	Helmholtz Zentrum München; Qiagen GmbH Hilden

The output of the NGFN from 2001 until 2008

includes over 80 patent applications, 2,400 scientific publications, and cooperation in 60 EU projects. The gain in insight into cause and process of disease development through the identification of molecular target structures has lead to a direct transfer of the results into development and optimization of diagnostics and therapeutics. A portfolio of results is ready for in-licensing or collaboration partnerships for further development. The scientists succeeded in discovering genetic variations with implications for Alzheimer's disease, epilepsy, Depression, Parkinson´s disease, cancer, susceptibility to allergies, adipositas, coronary heart disease, heart failure and enteritis. They developed DNA chips and identified gene signatures for neuroblastoma, Parkinson's disease, prostate cancer and heart failure that constitute a substantial advance in prognosis and diagnosis. They developed tools against autoimmune diseases, established systematic proof-of-principle approaches such as animal models and cell-based assays, used active semiconductor chips to develop highly complex peptide arrays and optimized micro-endoscopes for brain analysis. In one of the world's largest projects for the analysis of disease-causing genetic variations, the genetic information of up to 25,000 patients and controls is being examined with the help of DNA chips.